FindTrial
Sign In

Prediction of iodine-131 uptake function and prognosis in lung metastases of differentiated thyroid carcinoma

Prediction of iodine-131 uptake function and prognosis in lung metastases of differentiated thyroid carcinoma based on 18F-FDG PET/CT imaging

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800018047
Enrollment
Unknown
Registered
2018-08-28
Start date
2019-01-01
Completion date
Unknown
Last updated
2018-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thyroid cancer

Interventions

Gold Standard:Clinicopathological parameters (BRAF, TERT) and clinical biomarker information (thyroglobulin)
Index test:18F-FDG&#32
PET/CT&#32
imaging&#32
before&#32
radioiodine&#32
therapy&#32
for&#32
thyroid&#32
cancer&#32
with&#32
lung&#32
metastases

Sponsors

Shanghai Jiao Tong University Affiliated Sixth People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1 differentiated thyroid cancer lung metastasis; 2 no iodine treatment; 3 complete surgical and pathological data; 4 complete pre-treatment 18F-FDG PET/CT examination; 5 radioactive iodine treatment after iodine scan results; 6 complete Thyroid cancer index blood test (TSH, Tg, TgAb)before iodine treatment; 7 complete surgical pathology.

Exclusion criteria

Exclusion criteria: 1 undifferentiated thyroid carcinoma; 2 no radioactive iodine treatment; 3 surgical and pathological data is incomplete; 4 did not perform 18F-FDG PET/CT examination; 5 pathology and surgical data are unknown; 6 combined with other malignant tumor history.

Design outcomes

Primary

MeasureTime frame
Prediction of iodine -131 uptake and prognosis in differentiated lung cancer with lung metastases;—

Contacts

Public ContactHongjun Song
songhongjun0826@163.com15921044772

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026